UnknownPhase 1/2

Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo

Iran16 participantsStarted 2010-01

Plain-language summary

In this study 16 Patients diagnosed with Nonarteritic Anterior Ischemic Optic Neuropathy(NSION) who had a sudden mono ocular vision loss associated with optic disc edema and positive Marcus Gunn in less than 30 days without exclusion criteria are randomly divided in two groups 1) control 2) case. In case group Avastin and Triamcinolone will be injected trough vitreal and placebo will be injected in control group. BCVA and Visual field will be then measured in these two groups.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Sudden mono ocular vision loss associated with optic disc edema and positive Marcus Gunn (\<30 days) Exclusion criteria: * Any eye disease except NAION(Nonarteritic Anterior Ischemic Optic Neuropathy) * Neurologic defect * Abnormal ESR, CRP, any history of retina or vitreal surgery * Severe corneal opacity which makes retina examination impossible

What they're measuring

Changes of Best corrected visual acuity(BCVA)

Timeframe: 6 month

Trial details

NCT IDNCT01330524

SponsorShahid Beheshti University of Medical Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-11

View on ClinicalTrials.gov More Acute Nonarteritic Anterior Ischemic Optic Neuropathy trials